Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency

Completed · Phase 1

Conditions studied: Congenital Bleeding Disorder, Congenital FXIII Deficiency

In brief

This trial was conducted in the United States of America (USA). The aim of this trial was to investigate safety and pharmacokinetics of escalating single doses of catridecacog (recombinant factor XIII, rFXIII) in patients with congenital factor XIII deficiency.

Key facts

Study ID
NCT00056589
Run by
Novo Nordisk A/S
People needed
11
Starts
2003-03-01
Expected to finish
2003-10-01
Last updated by the study team
2017-01-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.